ABR AL ADWIYA DRUG STORE (DXB) - risultati della ricerca

tabrecta 200 mg

novartis israel ltd - capmatinib as dihydrochloride monohydrate - film coated tablets - capmatinib as dihydrochloride monohydrate 200 mg - capmatinib - tabrecta is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors have a mutation that leads to mesenchymal-epithelial transition (met) exon 14 skipping as detected by an approved test.

Israele - inglese - Ministry of Health

vocabria injection

glaxo smith kline (israel) ltd - cabotegravir - prolonged release suspension for injection - cabotegravir 200 mg / 1 ml - vocabria injection is indicated, in combination with rilpivirine injection, for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults who are virologically suppressed (hiv-1 rna <50 copies/ml) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the nnrti and ini class

Israele - inglese - Ministry of Health

vocabria tablets

glaxo smith kline (israel) ltd - cabotegravir as sodium - film coated tablets - cabotegravir as sodium 30 mg - vocabria tablets are indicated in combination with rilpivirine tablets for the short-term treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults who are virologically suppressed (hiv-1 rna <50 copies/ml) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the nnrti and ini class for: • oral lead in to assess tolerability of vocabria and rilpivirine prior to administration of long acting cabotegravir injection plus long acting rilpivirine injection. • oral therapy for adults who will miss planned dosing with cabotegravir injection plus rilpivirine injection.

Unione Europea - inglese - EMA (European Medicines Agency)

tabrecta

novartis europharm limited - capmatinib dihydrochloride monohydrate - carcinoma, non-small-cell lung - antineoplastic agents - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.